Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Lim ZF, Ma PC. · 2019

Read Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. by Lim ZF, Ma PC. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6902404.txt.

Description

Lim and Ma review drug resistance in targeted lung cancer therapy, in the Journal of Hematology and Oncology. Targeted drugs attack the driver mutations of a tumour. Their biggest limit is that resistance always emerges. In EGFR-mutant lung cancer, the commonest route is a second mutation in the same gene that weakens the drug's grip. First and second generation inhibitors fall to it in turn.

Other cancers bypass the blocked signal through side pathways, or transform into another cell type entirely. Giving targeted drugs one after another buys time but cannot outrun evolution, the authors argue. A small pool of tolerant cells may seed each relapse. They survey combination strategies, including chemo-immunotherapy, now used against resistant disease.

Catalog record

CREATORLim ZF, Ma PC.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE102 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6902404

Browse the full library · About the Tower of Babel